EDUCATION

Medical School

  • Warren Alpert Medical School of Brown University , 2007 , Providence , RI

Residency

Pediatrics
  • New York Presbyterian Hospital/ Weill Cornell Medical Center , 2011 , New York , NY

Fellowship

Pediatric Critical Care
  • Boston Children's Hospital , 2014 , Boston , MA

Fellowship

Transfusion Medicine
  • Brigham and Women’s Hospital/ Boston Children’s Hospital , 2015 , Boston , MA

CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics
  • American Board of Pathology, Blood Banking/Transfusion Medicine
  • American Board of Pediatrics, Critical Care Medicine

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism. ESC Heart Fail. 2021 Aug; 8(4):2698-2712. View abstract
  2. Correction to: Preschool-Onset Major Depressive Disorder is Characterized by Electrocortical Deficits in Processing Pleasant Emotional Pictures. Res Child Adolesc Psychopathol. 2021 Apr; 49(4):559-562. View abstract
  3. Life-Threatening Hemoptysis in a Pediatric Referral Center. Crit Care Med. 2021 03 01; 49(3):e291-e303. View abstract
  4. Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 04 06; 77(13):1660-1669. View abstract
  5. Novel Göttingen Miniswine Model of Heart Failure With Preserved Ejection Fraction Integrating Multiple Comorbidities. JACC Basic Transl Sci. 2021 Feb; 6(2):154-170. View abstract
  6. Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. Circ Heart Fail. 2021 01; 14(1):e007684. View abstract
  7. Practice Improvement for Standardized Evaluation and Management of Acute Tracheitis in Mechanically Ventilated Children. Pediatr Qual Saf. 2021 Jan-Feb; 6(1):e368. View abstract
  8. Neural Indicators of Anhedonia: Predictors and Mechanisms of Treatment Change in a Randomized Clinical Trial in Early Childhood Depression. Biol Psychiatry. 2020 12 01; 88(11):879-887. View abstract
  9. The Relationship Between Depression Symptoms and Adolescent Neural Response During Reward Anticipation and Outcome Depends on Developmental Timing: Evidence From a Longitudinal Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 05; 6(5):527-535. View abstract
  10. Quality Improvement Incorporating a Feedback Loop for Accurate Medication Reconciliation. Pediatrics. 2020 12; 146(6). View abstract
  11. Skeletal Muscle Energetics and Mitochondrial Function Are Impaired Following 10 Days of Bed Rest in Older Adults. J Gerontol A Biol Sci Med Sci. 2020 09 16; 75(9):1744-1753. View abstract
  12. A Case for Adaptive Cardiac Hypertrophic Remodeling Is CITED. Circ Res. 2020 08 14; 127(5):647-650. View abstract
  13. Extreme Acetylation of the Cardiac Mitochondrial Proteome Does Not Promote Heart Failure. Circ Res. 2020 09 25; 127(8):1094-1108. View abstract
  14. Corrigendum: Peer Victimization and Dysfunctional Reward Processing: ERP and Behavioral Responses to Social and Monetary Rewards. Front Behav Neurosci. 2020; 14:100. View abstract
  15. Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. Circulation. 2020 06 02; 141(22):1800-1812. View abstract
  16. A Critical Role for Estrogen-Related Receptor Signaling in Cardiac Maturation. Circ Res. 2020 06 05; 126(12):1685-1702. View abstract
  17. Peripheral Determinants of Oxygen Utilization in Heart Failure With Preserved Ejection Fraction: Central Role of Adiposity. JACC Basic Transl Sci. 2020 Mar; 5(3):211-225. View abstract
  18. Fueling Cardiac Hypertrophy. Circ Res. 2020 01 17; 126(2):197-199. View abstract
  19. Preschool-Onset Major Depressive Disorder is Characterized by Electrocortical Deficits in Processing Pleasant Emotional Pictures. J Abnorm Child Psychol. 2020 01; 48(1):91-108. View abstract
  20. Mitochondrial calcium exchange links metabolism with the epigenome to control cellular differentiation. Nat Commun. 2019 10 04; 10(1):4509. View abstract
  21. Unlocking the Secrets of Mitochondria in the Cardiovascular System: Path to a Cure in Heart Failure—A Report from the 2018 National Heart, Lung, and Blood Institute Workshop Circulation. 2019 10 01; 140(14):1205-1216. View abstract
  22. Loss of mitochondrial energetics is associated with poor recovery of muscle function but not mass following disuse atrophy. Am J Physiol Endocrinol Metab. 2019 11 01; 317(5):E899-E910. View abstract
  23. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. Cardiovasc Res. 2019 09 01; 115(11):1606-1616. View abstract
  24. MondoA drives muscle lipid accumulation and insulin resistance. JCI Insight. 2019 07 09; 5. View abstract
  25. Initiation of Noninvasive Ventilation for Acute Respiratory Failure in a Pediatric Intermediate Care Unit. Hosp Pediatr. 2019 07; 9(7):538-544. View abstract
  26. Peer Victimization and Dysfunctional Reward Processing: ERP and Behavioral Responses to Social and Monetary Rewards. Front Behav Neurosci. 2019; 13:120. View abstract
  27. Serendipitous drug repurposing through social media. Drug Discov Today. 2019 07; 24(7):1321-1323. View abstract
  28. Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation. 2019 03 12; 139(11):1435-1450. View abstract
  29. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight. 2019 02 21; 4(4). View abstract
  30. Respiratory Phenomics across Multiple Models of Protein Hyperacylation in Cardiac Mitochondria Reveals a Marginal Impact on Bioenergetics. Cell Rep. 2019 02 05; 26(6):1557-1572.e8. View abstract
  31. KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations. Mol Cancer Ther. 2019 03; 18(3):706-717. View abstract
  32. Neural Indicators of Anhedonia: Predictors and Mechanisms of Treatment Change in a Randomized Clinical Trial in Early Childhood Depression. Biol Psychiatry. 2019 05 15; 85(10):863-871. View abstract
  33. Single-Nucleotide Polymorphism of the MLX Gene Is Associated With Takayasu Arteritis. Circ Genom Precis Med. 2018 10; 11(10):e002296. View abstract
  34. Impaired Mitochondrial Energetics Characterize Poor Early Recovery of Muscle Mass Following Hind Limb Unloading in Old Mice. J Gerontol A Biol Sci Med Sci. 2018 09 11; 73(10):1313-1322. View abstract
  35. Sarcolipin Signaling Promotes Mitochondrial Biogenesis and Oxidative Metabolism in Skeletal Muscle. Cell Rep. 2018 09 11; 24(11):2919-2931. View abstract
  36. Skeletal muscle mitochondrial remodeling in exercise and diseases. Cell Res. 2018 10; 28(10):969-980. View abstract
  37. Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure? JACC Basic Transl Sci. 2017 Aug; 2(4):355-357. View abstract
  38. Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. Cell Metab. 2017 May 02; 25(5):1012-1026. View abstract
  39. Combination Clearance Therapy and Barbiturate Coma for Severe Carbamazepine Overdose. Pediatrics. 2017 May; 139(5). View abstract
  40. Skeletal muscle PGC-1ß signaling is sufficient to drive an endurance exercise phenotype and to counteract components of detraining in mice. Am J Physiol Endocrinol Metab. 2017 05 01; 312(5):E394-E406. View abstract
  41. Cardiac nuclear receptors: architects of mitochondrial structure and function. J Clin Invest. 2017 Apr 03; 127(4):1155-1164. View abstract
  42. Exercise Inducible Lactate Dehydrogenase B Regulates Mitochondrial Function in Skeletal Muscle. J Biol Chem. 2016 Dec 02; 291(49):25306-25318. View abstract
  43. Coupling of mitochondrial function and skeletal muscle fiber type by a miR-499/Fnip1/AMPK circuit. EMBO Mol Med. 2016 10; 8(10):1212-1228. View abstract
  44. Transfusion-related immunomodulation: review of the literature and implications for pediatric critical illness. Transfusion. 2017 01; 57(1):195-206. View abstract
  45. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 09 01; 126(9):3567-79. View abstract
  46. Quality improvement program reduces venous thromboembolism in infants and children with long-gap esophageal atresia (LGEA). Pediatr Surg Int. 2016 Jul; 32(7):691-6. View abstract
  47. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight. 2016 Feb; 2(1). View abstract
  48. Introducing JACC: Basic to Translational Science: Why Now? JACC Basic Transl Sci. 2016 Jan-Feb; 1(1-2):1-2. View abstract
  49. The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation. 2016 Feb 23; 133(8):698-705. View abstract
  50. Parkin-mediated mitophagy directs perinatal cardiac metabolic maturation in mice. Science. 2015 Dec 04; 350(6265):aad2459. View abstract
  51. Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes Dev. 2015 Oct 01; 29(19):1981-91. View abstract
  52. Maintaining ancient organelles: mitochondrial biogenesis and maturation. Circ Res. 2015 May 22; 116(11):1820-34. View abstract
  53. Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure. Clin Exp Pharmacol Physiol. 2015 Jan; 42(1):33-40. View abstract
  54. Mitochondrial function in melanoma. Arch Biochem Biophys. 2014 Dec 01; 563:56-9. View abstract
  55. High incidence of catheter-associated venous thromboembolic events in patients with long gap esophageal atresia treated with the Foker process. J Pediatr Surg. 2014 Feb; 49(2):370-3. View abstract
  56. Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the UDC database. Haemophilia. 2013 May; 19(3):426-31. View abstract
  57. Detecting pediatric delirium: development of a rapid observational assessment tool. Intensive Care Med. 2012 Jun; 38(6):1025-31. View abstract
  58. Novel communication between myocyte lipid storage and fat burning unveiled. Circ Res. 2012 Mar 02; 110(5):655-7. View abstract
  59. The nuclear receptor PPARß/d programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev. 2011 Dec 15; 25(24):2619-30. View abstract
  60. The transcriptional coactivators, PGC-1a and ß, cooperate to maintain cardiac mitochondrial function during the early stages of insulin resistance. J Mol Cell Cardiol. 2012 Mar; 52(3):701-10. View abstract
  61. Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor ? coactivator-1 signaling. Circ Heart Fail. 2011 Jul; 4(4):474-82. View abstract
  62. Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. J Biol Chem. 2011 Apr 01; 286(13):11155-62. View abstract
  63. Cell biology: Ageing theories unified. Nature. 2011 Feb 17; 470(7334):342-3. View abstract
  64. Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity. Cell Metab. 2010 Dec 01; 12(6):633-42. View abstract
  65. The PGC-1 cascade as a therapeutic target for heart failure. J Mol Cell Cardiol. 2011 Oct; 51(4):578-83. View abstract
  66. A PPARa promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. PLoS One. 2010 Sep 03; 5(9):e12584. View abstract
  67. Ubiquitin proteasome-dependent degradation of the transcriptional coactivator PGC-1{alpha} via the N-terminal pathway. J Biol Chem. 2010 Dec 17; 285(51):40192-200. View abstract
  68. Cardiovascular drug discovery in the academic setting: building infrastructure, harnessing strengths, and seeking synergies. J Cardiovasc Transl Res. 2010 Oct; 3(5):431-7. View abstract
  69. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ Res. 2010 Jul 23; 107(2):233-41. View abstract
  70. Introduction to the nuclear receptor review series. Circ Res. 2010 May 28; 106(10):1557-8. View abstract
  71. Interaction between the UCP2 -866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes. Pharmacogenet Genomics. 2010 Apr; 20(4):231-8. View abstract
  72. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation. 2010 Jan 26; 121(3):426-35. View abstract
  73. Impaired contractile function and calcium handling in hearts of cardiac-specific calcineurin b1-deficient mice. Am J Physiol Heart Circ Physiol. 2009 Oct; 297(4):H1263-73. View abstract
  74. Bcl3 interacts cooperatively with peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator 1alpha to coactivate nuclear receptors estrogen-related receptor alpha and PPARalpha. Mol Cell Biol. 2009 Aug; 29(15):4091-102. View abstract
  75. Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics. 2008 Oct; 9(10):1403-17. View abstract
  76. Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. Genes Dev. 2008 Jul 15; 22(14):1948-61. View abstract
  77. Differential effects of luminal arginine and glutamine on metalloproteinase production in the postischemic gut. JPEN J Parenter Enteral Nutr. 2008 Jul-Aug; 32(4):433-8. View abstract
  78. Signalling in cardiac metabolism. Cardiovasc Res. 2008 Jul 15; 79(2):205-7. View abstract
  79. The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol. 2008 Jul; 295(1):H185-96. View abstract
  80. PPARalpha-mediated remodeling of repolarizing voltage-gated K+ (Kv) channels in a mouse model of metabolic cardiomyopathy. J Mol Cell Cardiol. 2008 Jun; 44(6):1002-15. View abstract
  81. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol. 2008 Jun; 44(6):968-75. View abstract
  82. Hypoxic reprogramming. Nat Genet. 2008 Feb; 40(2):132-4. View abstract
  83. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest. 2007 Dec; 117(12):3930-9. View abstract
  84. A role for the transcriptional coactivator PGC-1alpha in muscle refueling. J Biol Chem. 2007 Dec 14; 282(50):36642-51. View abstract
  85. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab. 2007 Jul; 6(1):25-37. View abstract
  86. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation. 2007 May 15; 115(19):2540-8. View abstract
  87. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma. Cell Metab. 2007 May; 5(5):345-56. View abstract
  88. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res. 2007 Apr 27; 100(8):1208-17. View abstract
  89. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation. 2007 Feb 20; 115(7):909-17. View abstract
  90. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 2006 Sep; 4(3):199-210. View abstract
  91. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006 Mar; 116(3):615-22. View abstract
  92. PGC-1alpha coactivates PDK4 gene expression via the orphan nuclear receptor ERRalpha: a mechanism for transcriptional control of muscle glucose metabolism. Mol Cell Biol. 2005 Dec; 25(24):10684-94. View abstract
  93. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation. 2005 Oct 11; 112(15):2339-46. View abstract
  94. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. . 2006 Jan; 290(1):H87-95. View abstract
  95. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology. 2005 Sep; 42(3):568-77. View abstract
  96. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes. 2005 Sep; 54(9):2514-24. View abstract
  97. Cost of transport is increased after cold exposure in Monodelphis domestica: training for inefficiency. J Exp Biol. 2005 Aug; 208(Pt 16):3159-67. View abstract
  98. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005 Apr; 3(4):e101. View abstract
  99. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest. 2005 Mar; 115(3):547-55. View abstract
  100. A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes. Cell Metab. 2005 Feb; 1(2):133-44. View abstract
  101. Mouse models of mitochondrial dysfunction and heart failure. J Mol Cell Cardiol. 2005 Jan; 38(1):81-91. View abstract
  102. G-protein signaling participates in the development of diabetic cardiomyopathy. Diabetes. 2004 Dec; 53(12):3082-90. View abstract
  103. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol. 2004 Oct; 24(20):9079-91. View abstract
  104. Nuclear receptor signaling and cardiac energetics. Circ Res. 2004 Sep 17; 95(6):568-78. View abstract
  105. Calcineurin and calcium/calmodulin-dependent protein kinase activate distinct metabolic gene regulatory programs in cardiac muscle. J Biol Chem. 2004 Sep 17; 279(38):39593-603. View abstract
  106. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004 Feb 15; 18(4):357-68. View abstract
  107. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004 Mar 05; 94(4):525-33. View abstract
  108. Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPARalpha in fasting mice. FASEB J. 2004 Feb; 18(2):347-9. View abstract
  109. Developmental adaptation of the mouse cardiovascular system to elastin haploinsufficiency. J Clin Invest. 2003 Nov; 112(9):1419-28. View abstract
  110. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med. 2003 Aug; 9(8):1069-75. View abstract
  111. PPARs of the heart: three is a crowd. Circ Res. 2003 Mar 21; 92(5):482-4. View abstract
  112. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A. 2003 Feb 04; 100(3):1226-31. View abstract
  113. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension. 2003 Jan; 41(1):83-7. View abstract
  114. Retinoid X receptor alpha represses GATA-4-mediated transcription via a retinoid-dependent interaction with the cardiac-enriched repressor FOG-2. J Biol Chem. 2003 Feb 21; 278(8):5760-7. View abstract
  115. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J. 2002 Dec; 16(14):1879-86. View abstract
  116. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol. 2002 Oct; 34(10):1249-57. View abstract
  117. Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. J Biol Chem. 2002 Oct 25; 277(43):40265-74. View abstract
  118. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002 Jul 17; 40(2):271-7. View abstract
  119. PPARalpha suppresses insulin secretion and induces UCP2 in insulinoma cells. J Lipid Res. 2002 Jun; 43(6):936-43. View abstract
  120. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol. 2002 Apr; 29(4):339-45. View abstract
  121. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev. 2002 Apr; 7(2):175-85. View abstract
  122. Peroxisome proliferator-activated receptor alpha as a genetic determinant of cardiac hypertrophic growth: culprit or innocent bystander? Circulation. 2002 Mar 05; 105(9):1025-7. View abstract
  123. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002 Jan; 109(1):121-30. View abstract
  124. A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem. 2002 Feb 08; 277(6):4098-103. View abstract